<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Key stakeholders’ perspectives on implementation of risk-based population breastcancer screening in Australia – “We can either get on the bus or get under it” -PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>
</head>
<body>
  <h1>Key stakeholders’ perspectives on implementation of risk-based population breastcancer screening in Australia – “We can either get on the bus or get under it” -PMC</h1>
  
  <div class="share-block">
    <span>🔗 分享這篇SEO：</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fkey-stakeholders-perspectives-on-implementation-of-riskbased-population-breastcancer-screening-in-australia-we-can-either-get-on-the-bus-or-get-under-it-pmc-seo.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fkey-stakeholders-perspectives-on-implementation-of-riskbased-population-breastcancer-screening-in-australia-we-can-either-get-on-the-bus-or-get-under-it-pmc-seo.html&text=Key%20stakeholders%E2%80%99%20perspectives%20on%20implementation%20of%20risk-based%20population%20breastcancer%20screening%20in%20Australia%20%E2%80%93%20%E2%80%9CWe%20can%20either%20get%20on%20the%20bus%20or%20get%20under%20it%E2%80%9D%20-PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fkey-stakeholders-perspectives-on-implementation-of-riskbased-population-breastcancer-screening-in-australia-we-can-either-get-on-the-bus-or-get-under-it-pmc-seo.html&text=Key%20stakeholders%E2%80%99%20perspectives%20on%20implementation%20of%20risk-based%20population%20breastcancer%20screening%20in%20Australia%20%E2%80%93%20%E2%80%9CWe%20can%20either%20get%20on%20the%20bus%20or%20get%20under%20it%E2%80%9D%20-PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  
  <div style="text-align: center;">
    <img src="https://i.imgur.com/H4JFuyI.png" alt="SEO Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;">
  </div>

  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">中文</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">日本語</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQI9CDgh7JwzUGH4QTfT5Su2MGI3gUURdf3Tw&s" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        廣告
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style=""><!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2025 年乳癌篩檢新趨勢：個人化風險評估與篩檢策略 (Personalized Breast Cancer Screening)</title>
    <meta name="description" content="深入探討 2025 年乳癌篩檢的最新趨勢，包括個人化風險評估、篩檢策略的演變、以及實施上的挑戰。了解如何根據個人風險因子調整篩檢計畫，提升篩檢效益。">
    <style>
        body { font-family: sans-serif; line-height: 1.6; }
        h1, h2, h3 { color: #333; }
        a { color: #007bff; text-decoration: none; }
        a:hover { text-decoration: underline; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; text-align: left; }
        th { background-color: #f2f2f2; }
    </style>
</head>
<body>

<h1>2025 年乳癌篩檢新趨勢：個人化風險評估與篩檢策略 (Personalized Breast Cancer Screening)</h1>

<nav id="toc">
    <h2>目錄 (導讀)</h2>
    <ul>
        <li><a href="#introduction">導讀：從「一刀切」到個人化</a></li>
        <li><a href="#background">背景解析：乳癌篩檢的演變與挑戰</a></li>
        <li><a href="#highlights">重點解讀：個人化篩檢的關鍵議題</a></li>
        <li><a href="#expert-opinion">專家觀點：篩檢策略的未來</a></li>
        <li><a href="#conclusion">結論與行動呼籲：為自己與家人的健康把關</a></li>
    </ul>
</nav>

<h2 id="introduction">導讀：從「一刀切」到個人化</h2>

<p>想像一下，您是一位媽媽，每年都按照醫生建議進行乳癌篩檢。但您是否曾想過，這個「標準流程」是否真的適合您？過去，乳癌篩檢往往採取「一刀切」的方式，所有女性都遵循相同的篩檢時間表。然而，隨著醫學研究的進步，我們越來越認識到，每個人面對乳癌的風險都不同。2025 年，乳癌篩檢正走向個人化時代，根據您的個人風險因子，量身打造篩檢計畫，這不僅能提升篩檢效益，也能減少不必要的焦慮和醫療資源浪費。</p>

<h2 id="background">背景解析：乳癌篩檢的演變與挑戰</h2>

<p>乳癌篩檢的歷史可以追溯到 20 世紀中葉。最初的篩檢方法主要依賴乳房攝影 (Mammography)，旨在早期發現潛在的腫瘤。然而，隨著時間推移，我們逐漸認識到，僅僅依靠乳房攝影並不足以全面降低乳癌死亡率。</p>

<table>
    <thead>
        <tr>
            <th>年份</th>
            <th>主要篩檢方法</th>
            <th>主要挑戰</th>
        </tr>
        <tr>
            <td>1970 年代</td>
            <td>乳房攝影</td>
            <td>誤判率高、對年輕女性的效益有限</td>
        </tr>
        <tr>
            <td>1990 年代</td>
            <td>乳房攝影 + 自我檢查</td>
            <td>自我檢查的效益存疑</td>
        </tr>
        <tr>
            <td>2000 年代</td>
            <td>乳房攝影 + 超音波</td>
            <td>仍需更精準的風險評估</td>
        </tr>
        <tr>
            <td>2020 年代</td>
            <td>乳房攝影 + 個人化風險評估</td>
            <td>實施上的複雜性、公眾接受度</td>
        </tr>
    </table>

<p>目前，乳癌篩檢面臨的主要挑戰包括：如何更精確地評估個人風險、如何提高篩檢的效益、以及如何讓公眾更容易接受新的篩檢策略。此外，不同國家和地區的乳癌發生率和篩檢資源也存在差異，需要制定符合當地情況的篩檢方案。</p>

<h2 id="highlights">重點解讀：個人化篩檢的關鍵議題</h2>

<p>個人化乳癌篩檢的核心在於根據個人的風險因子，調整篩檢的時間和方法。這些風險因子可能包括：家族病史、基因突變、生活習慣、以及其他健康狀況。以下是一些個人化篩檢的關鍵議題：</p>

<table>
    <thead>
        <tr>
            <th>議題</th>
            <th>說明</th>
        </tr>
        <tr>
            <td><b>風險評估工具</b></td>
            <td>如何利用精確的工具評估個人乳癌風險？</td>
        </tr>
        <tr>
            <td><b>篩檢時間</b></td>
            <td>根據風險等級，調整篩檢開始年齡和間隔時間。</td>
        </tr>
        <tr>
            <td><b>篩檢方法</b></td>
            <td>除了乳房攝影，是否需要搭配超音波、MRI 或基因檢測？</td>
        </tr>
        <tr>
            <td><b>公眾溝通</b></td>
            <td>如何向大眾解釋個人化篩檢的優點和局限性？</td>
        </tr>
    </table>

<p>值得注意的是，一些研究正在探索利用人工智慧 (Artificial Intelligence, AI) 技術，協助醫生分析影像資料，提高篩檢的準確性。例如，AI 可以幫助醫生更早地發現潛在的腫瘤，減少誤判的機會。</p>

<h2 id="expert-opinion">專家觀點：篩檢策略的未來</h2>

<p>「個人化篩檢代表了乳癌篩檢的未來趨勢。」一位乳癌專家表示：「過去的篩檢策略往往忽略了個體差異，導致一些高風險女性未能及早發現乳癌，而另一些低風險女性則承受了不必要的篩檢負擔。透過個人化篩檢，我們可以更有效地利用醫療資源，為更多女性提供更好的保護。」</p>

<p>專家也提醒，個人化篩檢並非萬能，它仍然存在一些局限性。例如，目前的風險評估工具可能並非完全準確，而且一些高風險女性可能仍然無法及早發現乳癌。因此，我們需要持續改進篩檢策略，並鼓勵女性積極參與健康管理。</p>

<h2 id="conclusion">結論與行動呼籲：為自己與家人的健康把關</h2>

<p>2025 年，乳癌篩檢將進入個人化時代。這意味著，我們有機會根據自己的風險因子，量身打造篩檢計畫，提升篩檢效益。然而，個人化篩檢並非一蹴可幾，它需要醫生的專業知識、科技的進步、以及大眾的積極參與。</p>

<p><b>行動呼籲：</b></p>
<ul>
    <li>與您的醫生討論您的個人風險因子，制定適合您的篩檢計畫。</li>
    <li>了解最新的篩檢資訊，並與您的家人分享。</li>
    <li>積極參與健康管理，保持健康的生活方式。</li>
</ul>

<p>讓我們一起為自己與家人的健康把關，共同迎接乳癌篩檢的新時代！</p>

<p><b>參考資料：</b><a href="https://pmc.ncbi.nlm.nih.gov/articles/12400751/">https://pmc.ncbi.nlm.nih.gov/articles/12400751/</a></p>

</body>
</html></div><div class="lang-content" data-lang="en" style="display: none;"><!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Personalized Breast Cancer Screening: A New Era Dawns in 2025</title>
    <meta name="description" content="Explore the future of breast cancer screening in 2025. Learn about risk-based approaches, AI advancements, and patient perspectives shaping a more personalized and effective screening process.">
    <style>
        /* Basic styling for readability - feel free to expand */
        body { font-family: Arial, sans-serif; line-height: 1.6; }
        h1, h2, h3 { color: #333; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; }
        th { background-color: #f2f2f2; }
    </style>
</head>
<body>

    <h1>Personalized Breast Cancer Screening: A New Era Dawns in 2025</h1>

    <h2 id="toc">Table of Contents</h2>
    <ul>
        <li><a href="#introduction">Introduction</a></li>
        <li><a href="#background">Background: Why One-Size-Fits-All Screening Isn't Enough</a></li>
        <li><a href="#highlights">Key Takeaways: What's Changing in Breast Cancer Screening</a></li>
        <li><a href="#expert-opinion">Expert Opinion: Reflecting on the Future of Screening</a></li>
        <li><a href="#conclusion">Conclusion & Call to Action: Staying Informed and Advocating for Change</a></li>
    </ul>

    <h2 id="introduction">Introduction: A More Tailored Approach to Breast Health</h2>

    Imagine a future where your breast cancer screening isn't based on a general guideline, but on *your* individual risk factors. That future is rapidly approaching, and by 2025, we're poised to see a significant shift towards personalized breast cancer screening. For decades, screening guidelines have largely followed a "one-size-fits-all" approach, recommending regular mammograms for women over a certain age. But emerging research and technological advancements are revealing that this approach isn't always the most effective or appropriate. This article explores the evolving landscape of breast cancer screening, examining the research, the challenges, and the exciting possibilities that lie ahead.

    <h2 id="background">Background: Why One-Size-Fits-All Screening Isn't Enough</h2>

    The current standard for breast cancer screening has been largely based on population-level data. While this has undoubtedly saved lives, it also means that some women are screened unnecessarily, leading to anxiety, false positives (incorrectly identifying cancer), and potentially unnecessary biopsies. Conversely, other women at higher risk may not be screened frequently enough, potentially delaying diagnosis and impacting outcomes.

    The need for a more nuanced approach is supported by several factors:

    *   **Varying Risk Factors:** Breast cancer risk isn't uniform. Factors like family history, genetics (e.g., BRCA1 and BRCA2 mutations), age, ethnicity, lifestyle choices, and even reproductive history all contribute to an individual's risk.
    *   **Overdiagnosis:**  Screening can sometimes detect cancers that would never have caused harm during a woman's lifetime – these are known as overdiagnosed cancers.  This can lead to unnecessary treatment and anxiety.
    *   **Uneven Outcomes:**  Screening effectiveness can vary significantly across different populations, highlighting the need for tailored strategies.

    Several key research efforts are driving this shift.  The Lancet Oncology (32) has been a vocal advocate for personalized screening, arguing that a "one-size-fits-all" approach is no longer sustainable.  Classic principles of disease screening, as outlined by Wilson & Jungner (36), provide a foundational understanding of the complexities involved.  In Australia, the Daffodil Centre’s ROSA (Roadmap for Optimising Screening in Australia) project (31) is actively investigating risk-based screening strategies.

    Here's a table summarizing some key research and initiatives:

    <table>
        <thead>
            <tr>
                <th>Initiative/Research</th>
                <th>Focus</th>
                <th>Source</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>The Lancet Oncology (32)</td>
                <td>Advocating for personalized screening</td>
                <td>(32)</td>
            </tr>
            <tr>
                <td>Wilson & Jungner (36)</td>
                <td>Foundational principles of disease screening</td>
                <td>(36)</td>
            </tr>
            <tr>
                <td>Daffodil Centre ROSA Project (31)</td>
                <td>Investigating risk-based screening in Australia</td>
                <td>(31)</td>
            </tr>
            <tr>
                <td>Velentzis et al. (34)</td>
                <td>Systematic review of risk assessment tools</td>
                <td>(34)</td>
            </tr>
        </tbody>
    </table>

    <h2 id="highlights">Key Takeaways: What's Changing in Breast Cancer Screening</h2>

    The move towards personalized breast cancer screening involves several key changes:

    *   **Risk Assessment:**  More sophisticated risk assessment tools are being developed and implemented to accurately stratify women into different risk categories. Velentzis et al. (34) conducted a systematic review of these tools, highlighting their potential to improve screening strategies.
    *   **Tailored Screening Intervals:**  Women at higher risk may be screened more frequently, while those at lower risk may be screened less often or may consider alternative screening methods.
    *   **Supplemental Screening:**  For women at increased risk, supplemental screening methods like MRI (Magnetic Resonance Imaging) may be recommended in addition to mammography.  The "screenTrustMRI" trial (Salim et al., 29) is exploring the use of AI-based selection to identify women who would benefit most from supplemental MRI.
    *   **Patient-Centered Approach:**  The process emphasizes shared decision-making between patients and healthcare providers, taking into account individual preferences and values.  Research by Taylor et al. (30) and Wheeler et al. (35) underscores the importance of understanding patient perspectives and addressing concerns about risk stratification.

    Here's a table summarizing the key changes:

    <table>
        <thead>
            <tr>
                <th>Change</th>
                <th>Description</th>
                <th>Source</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Risk Assessment</td>
                <td>Using tools to categorize women by risk level</td>
                <td>(34)</td>
            </tr>
            <tr>
                <td>Screening Intervals</td>
                <td>Adjusting frequency based on risk</td>
                <td>(32)</td>
            </tr>
            <tr>
                <td>Supplemental Screening</td>
                <td>Using MRI for higher-risk women</td>
                <td>(29)</td>
            </tr>
            <tr>
                <td>Patient-Centered Approach</td>
                <td>Shared decision-making</td>
                <td>(30, 35)</td>
            </tr>
        </tbody>
    </table>

    <h2 id="expert-opinion">Expert Opinion: Reflecting on the Future of Screening</h2>

    Imagine a future where your doctor doesn't just tell you to get a mammogram, but engages in a conversation about your individual risk factors, your values, and your preferences. This isn's just a pipe dream; it's a vision of the future of breast cancer screening.  But this shift requires more than just technological advancements. It demands a fundamental change in how we approach healthcare – moving from a reactive, population-based model to a proactive, personalized one.

    What are your thoughts on this transition? Are you comfortable with the idea of being categorized into a risk group? What questions would you ask your doctor about your individual screening plan?  The future of breast cancer screening isn't just about science; it's about empowering patients to take control of their health and make informed decisions.  The research by Tong et al. (33) highlights the importance of clear and transparent communication in qualitative research, a principle that should extend to patient-doctor interactions.  Furthermore, the collaborative action and program theory explored by Rycroft-Malone et al. (28) are crucial for successfully implementing these new screening approaches.

    <h2 id="conclusion">Conclusion & Call to Action</h2>

    The landscape of breast cancer screening is undergoing a profound transformation. By 2025, we can expect to see a greater emphasis on personalized approaches, leveraging risk assessment tools, technological advancements, and patient-centered care. While challenges remain – including ensuring equitable access to these advanced screening methods and addressing patient concerns – the potential benefits are significant.

    **Call to Action:**

    *   **Stay Informed:** Continue to follow developments in breast cancer screening research and guidelines.
    *   **Discuss Your Risk:** Talk to your doctor about your individual risk factors and screening options.
    *   **Advocate for Change:** Support initiatives that promote equitable access to personalized screening methods.
    *   **Share this article:** Help spread awareness about the evolving landscape of breast cancer screening.

    The future of breast health is in our hands. Let's work together to ensure that every woman has the opportunity to receive the screening that's right for her.
</body>
</html></div><div class="lang-content" data-lang="jp" style="display: none;"><!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>2025年：乳がん検診は個別化へ？リスクに応じた新しい検診とは</title>
  <meta name="description" content="乳がん検診は、すべての人に同じ方法で行うのではなく、個々のリスクに合わせて行う時代へ。最新の研究や専門家の意見をわかりやすく解説します。">
  <meta name="keywords" content="乳がん検診, リスク, 個別化, AI, 専門家, 2025年, 早期発見, 検査, 医療">
</head>
<body>

  <h1>2025年：乳がん検診は個別化へ？リスクに応じた新しい検診とは</h1>

  <nav id="toc">
    <h2>目次</h2>
    <ul>
      <li><a href="#introduction">導入：みんな違って、でもみんな大切な検診</a></li>
      <li><a href="#background">背景：なぜ、これまでの検診方法を見直すのか？</a></li>
      <li><a href="#highlights">ポイント解説：リスクに応じた検診って、どういうこと？</a></li>
      <li><a href="#expert-opinion">専門家の意見：個別化検診のメリットと課題</a></li>
      <li><a href="#conclusion">結論と行動呼びかけ：未来の検診への期待と、今できること</a></li>
    </ul>
  </nav>

  <h2 id=introduction>導入：みんな違って、でもみんな大切な検診</h2>

  <p>「乳がん検診って、定期的に受けるもの」と思っていませんか？確かに、早期発見のために大切な検診ですが、実は、これまでの「すべての人に同じ方法で検診する」やり方は、見直される動きがあります。2025年以降、乳がん検診は、個々のリスクに合わせて、よりパーソナルなものへと進化していくかもしれません。今回は、最新の研究や専門家の意見を参考に、この新しい検診の方向性について、わかりやすくご紹介します。</p>

  <h2 id=background>背景：なぜ、これまでの検診方法を見直すのか？</h2>

  <p>これまで、乳がん検診は、すべての人に一定の間隔でマンモグラフィ（乳房X線撮影）を受けることが推奨されてきました。しかし、この方法は、検診を受ける人にとって負担になる場合があることや、過剰な検査による不必要な心配を引き起こす可能性があることが指摘されています。</p>

  <p>例えば、乳がんのリスクが低い人は、頻繁に検査を受ける必要がないかもしれませんし、逆に、リスクが高い人は、より頻繁に、あるいは、より詳細な検査を受ける必要があるかもしれません。すべての人に同じ方法で検診するのではなく、個々のリスクに合わせて、検査の種類や頻度を調整することが、より効果的で、負担の少ない検診方法と言えるでしょう。</p>

  <table>
    <caption>乳がん検診の課題</caption>
    <thead>
      <tr>
        <th>課題</th>
        <th>詳細</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td>過剰な検査</td>
        <td>リスクの低い人への頻繁な検査は、不必要な心配や負担になる</td>
      </tr>
      <tr>
        <td>見逃しの可能性</td>
        <td>リスクの高い人の検査が不十分だと、早期発見が遅れる可能性</td>
      </tr>
      <tr>
        <td>費用</td>
        <td>すべての人に同じ検査を行うと、医療費が増大する</td>
      </tr>
    </tbody>
  </table>

  <p>この背景には、世界保健機関（WHO）の初期の提唱（Wilson JMG, Jungner G, World Health, O. (1968)）や、The Lancet Oncologyの editorial（The Lancet Oncology. (2023)）など、検診の原則や効果を再評価する動きがあります。</p>

  <h2 id=highlights>ポイント解説：リスクに応じた検診って、どういうこと？</h2>

  <p>リスクに応じた検診とは、乳がんのリスクを評価し、その結果に基づいて、検査の種類や頻度を調整する検診方法です。リスク評価には、年齢、家族歴、遺伝的要因、生活習慣など、様々な要素が考慮されます。</p>

  <p>例えば、乳がんのリスクが高い人は、マンモグラフィに加えて、MRI（磁気共鳴画像）検査を受ける必要があるかもしれません。また、リスクが低い人は、マンモグラフィの頻度を減らすことができるかもしれません。</p>

  <p>この際、患者さんがリスクに応じた検診をどのように受け止めるか（Taylor LC, Hutchinson A, Law K, Shah V, UsherSmith JA, Dennison RA. (2023)）や、女性たちがリスクと検査の価値観がどのように異なるか（Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, Ijzerman MJ, Trainer AH. (2022)）を理解することが重要です。</p>

  <p>リスク評価には、様々なツールが利用されています（Velentzis, LS, Freeman, V, Campbell, D, Hughes, S, Luo, Q, Steinberg, J, Egger, S, Mann, GB, Nickson, C (2023)）。これらのツールを使って、個々のリスクを正確に評価し、適切な検査を選択することが、個別化検診の鍵となります。</p>

  <p>また、AI（Salim M, Liu Y, Sorkhei M, Ntoula D, Foukakis T, Fredriksson I, Wang Y, Eklund M, Azizpour H, Smith K, Strand F. (2024)）を活用して、より効率的にリスクを評価し、MRI検査が必要な人を特定することも検討されています。</p>

  <h2 id=expert-opinion>専門家の意見：個別化検診のメリットと課題</h2>

  <p>「個別化検診は、患者さんにとって負担を軽減し、より効果的な検診を提供できる可能性を秘めています。しかし、リスク評価の精度や、患者さんへの十分な説明が不可欠です。また、医療従事者の負担が増加する可能性も考慮する必要があります。」</p>

  <p>「皆さんは、リスクに応じた検診について、どのように思いますか？もし、ご自身の検診方法について、医師と相談する機会があれば、積極的に意見を伝えてみてください。」</p>

  <h2 id=conclusion>結論と行動呼びかけ</h2>

  <p>乳がん検診は、早期発見のために非常に重要なものです。しかし、これまでの「すべての人に同じ方法で検診する」やり方は、見直されるべき時が来ています。2025年以降、乳がん検診は、個々のリスクに合わせて、よりパーソナルなものへと進化していくでしょう。</p>

  <p>この変化は、患者さんにとって、より負担が少なく、効果的な検診を受ける機会を提供します。しかし、そのために、医療従事者と患者さんが協力し、リスク評価の精度を高め、患者さんへの十分な説明を行うことが不可欠です。</p>

  <p>皆さんも、この新しい検診の方向性に注目し、ご自身の検診方法について、医師と積極的に相談してみてください。未来の検診は、皆さんの健康を守るための、より良い選択肢を提供してくれるはずです。</p>

  <p>参考文献：<br>
  Wilson JMG, Jungner G, World Health, O. (1968). Principles and practice of screening for disease.<br>
  The Lancet Oncology. (2023). Breast cancer screening one size does not fit all.<br>
  Taylor LC, Hutchinson A, Law K, Shah V, UsherSmith JA, Dennison RA. (2023). Acceptability of risk stratification within populationbased cancer screening from the perspective of the general public a mixedmethods systematic review.<br>
  Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, Ijzerman MJ, Trainer AH. (2022). Heterogeneity in how women value riskstratified breast screening.<br>
  Velentzis, LS, Freeman, V, Campbell, D, Hughes, S, Luo, Q, Steinberg, J, Egger, S, Mann, GB, Nickson, C (2023). Breast Cancer Risk Assessment Tools for Stratifying Women into Risk Groups A Systematic Review.<br>
  Salim M, Liu Y, Sorkhei M, Ntoula D, Foukakis T, Fredriksson I, Wang Y, Eklund M, Azizpour H, Smith K, Strand F. (2024). AIbased selection of individuals for supplemental MRI in populationbased breast cancer screening the randomized screentrustmri trial.</p>

</body>
</html></div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="https://pmc.ncbi.nlm.nih.gov/articles/12400751/" target="_blank">👉 查看原始新聞</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>